<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104427</url>
  </required_header>
  <id_info>
    <org_study_id>TG-0054-04</org_study_id>
    <nct_id>NCT02104427</nct_id>
  </id_info>
  <brief_title>PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients</brief_title>
  <official_title>A Phase II, Open-Label Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TaiGen Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TaiGen Biotechnology Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF
      in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin
      lymphoma or Hodgkin disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients From Whom a Total Number of CD34+ Cells ≥5.0 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions</measure>
    <time_frame>Day 5 to Day 8</time_frame>
    <description>The primary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥5.0 x 10^6 cells/kg was collected within the first 4 leukapheresis sessions. For the primary efficacy endpoint, each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients From Whom a Total Number of CD34+ Cells ≥2.5 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions</measure>
    <time_frame>Day 5 to Day 8</time_frame>
    <description>The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥2.5 x 10^6 cells/kg was collected within the first 4 leukapheresis sessions. Each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Mobilized the Targeted Total Number of CD34+ Cells (≥6.0 x 10^6 Cells/kg) Within 5 Leukapheresis Sessions</measure>
    <time_frame>Day 5 to Day 9</time_frame>
    <description>The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥6.0 x 10^6 cells/kg was collected within 5 leukapheresis sessions. Each patient's CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) 5 leukapheresis sessions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Pharmacodynamics (PD) Following Treatment With TG-0054 When Combined With G-CSF</measure>
    <time_frame>Day 5 (1st leukapheresis session) to Day 6 (2nd leukapheresis session)</time_frame>
    <description>determine circulating CD34+ cell counts in peripheral blood</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>TG-0054 combined with G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1. G-CSF: 10 μg/kg/day, administrated via SC injections from Day 1 to Day 8; 2. TG-0054: 3.14 mg/kg, administrated via 15-min IV infusion from Day 5 to Day 9 as needed to reach the target collection goal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG-0054 combined with G-CSF</intervention_name>
    <arm_group_label>TG-0054 combined with G-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 to 75 years of age inclusive;

          -  Patients with confirmed pathology diagnosis of MM, NHL or HD;

          -  Potential candidate for autologous stem cell transplantation at Investigator's
             discretion;

          -  &gt; 4 weeks since last cycle of chemotherapy prior to the study drug administration;

          -  Total dose of melphalan received ≦ 200 mg in the most recent chemotherapy treatment;

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

          -  Recovered from all acute toxic effects of prior chemotherapy at Investigator's
             discretion;

          -  White blood cell (WBC) count ≧ 3.0*10^9/L on screening laboratory assessments;

          -  Absolute neutrophil count ≧ 1.5*10^9/L on screening laboratory assessments;

          -  Platelet count ≧ 100*10^9/L on screening laboratory assessments;

          -  Serum creatinine ≦ 2.2 mg/dL on screening laboratory assessments;

          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin
             &lt; 2 x upper limit of normal (ULN) on screening laboratory assessments;

          -  Negative for human immunodeficiency virus (HIV);

          -  Adequate cardiac and pulmonary function to undergo leukapheresis at Investigator's
             discretion;

          -  For females, one of the following criteria must be fulfilled:

               1. At least one year post-menopausal, or

               2. Surgically sterile, or

               3. Willing to use a double-barrier method [intrauterine device (IUD) plus condom,
                  spermicidal gel plus condom] of contraception from study Day 1 until 28 days
                  after the last dose of TG-0054;

          -  Males must be willing to use a reliable form of contraception (use of a condom or a
             partner fulfilling the above criteria) from study Day 1 until 28 days after the last
             dose of TG-0054;

          -  Able to provide the signed informed consent.

        Exclusion Criteria:

          -  Received radiation therapy to the pelvis;

          -  Received &gt; 6 cycles of lenalidomide;

          -  Evidence of bone marrow involvement of lymphoma in NHL patients;

          -  Failed previous stem cell collection [failed to collect 2.0*10^6 CD34+ cells/kg within
             4 leukapheresis sessions after receiving granulocyte colony-stimulating factor
             (G-CSF)];

          -  Patients who have undergone previous stem cell transplantation procedure;

          -  Received G-CSF within 2 weeks prior to the study drug administration;

          -  History of other cancer within the past 5 years excluding MM, NHL, HD, basal cell or
             squamous cell carcinoma of the skin;

          -  History of other hematologic disorders including bleeding or thromboembolic disease
             being treated with anti-coagulant;

          -  History of poor and uncontrollable cardiovascular or pulmonary disease such as
             myocardial infarction, cardiac arrhythmias, transient ischemic attack, stroke or
             Chronic Obstructive Pulmonary Disease (COPD) patients hospitalized more than two times
             a year due to underlying disease;

          -  Diagnosis of sickle cell anemia or documented sickle cell trait;

          -  Patients with proliferative retinopathy;

          -  Uncontrollable malignancy with MM, NHL or HD, or carcinomatous meningitis, at
             Investigator's discretion;

          -  Any infection required antibiotic treatment or unexplained fever above 38 °C within 3
             days prior to dosing;

          -  Pregnant or breast-feeding;

          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
             treatment of either a psychiatric or physical (e.g., infectious disease) illness must
             not be enrolled into this study;

          -  Received any other investigational drug within 1 month before entering the study;

          -  Received prior treatment with TG-0054 but withdrew early from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael M Schuster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stony Brook University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <results_first_submitted>October 12, 2017</results_first_submitted>
  <results_first_submitted_qc>December 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2017</results_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TG-0054 Combined With G-CSF</title>
          <description>1. G-CSF: 10 μg/kg/day, administrated via SC injections from Day 1 to Day 8; 2. TG-0054: 3.14 mg/kg, administrated via 15-min IV infusion from Day 5 to Day 9 as needed to reach the target collection goal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TG-0054 Combined With G-CSF</title>
          <description>1. G-CSF: 10 μg/kg/day, administrated via SC injections from Day 1 to Day 8; 2. TG-0054: 3.14 mg/kg, administrated via 15-min IV infusion from Day 5 to Day 9 as needed to reach the target collection goal.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="41" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.4" lower_limit="54.6" upper_limit="114.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.3" lower_limit="21.9" upper_limit="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients From Whom a Total Number of CD34+ Cells ≥5.0 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions</title>
        <description>The primary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥5.0 x 10^6 cells/kg was collected within the first 4 leukapheresis sessions. For the primary efficacy endpoint, each patient’s CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.</description>
        <time_frame>Day 5 to Day 8</time_frame>
        <population>There were total 9 MM patients and 3 NHL or HD patients . A MM patient was treated with Revlimid, Following 2 leukapheresis sessions, a cumulative total of 0.18 x 10^6 cells/kg were collected. PI and Medical Monitor didn't feel that further leukapheresis sessions would achieve more cells, so the patient didn't have additional sessions.</population>
        <group_list>
          <group group_id="O1">
            <title>Within 1 Leukapheresis Session</title>
            <description>Cumulative CD34+ cell counts ≥5.0 x 10^6 cells/kg within 1 leukapheresis session</description>
          </group>
          <group group_id="O2">
            <title>Within 2 Leukapheresis Sessions</title>
            <description>Cumulative CD34+ cell counts ≥5.0 x 10^6 cells/kg within 2 leukapheresis session</description>
          </group>
          <group group_id="O3">
            <title>Within 3 Leukapheresis Sessions</title>
            <description>Cumulative CD34+ cell counts ≥5.0 x 10^6 cells/kg within 3 leukapheresis session</description>
          </group>
          <group group_id="O4">
            <title>Within 4 Leukapheresis Sessions</title>
            <description>Cumulative CD34+ cell counts ≥5.0 x 10^6 cells/kg within 4 leukapheresis session</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients From Whom a Total Number of CD34+ Cells ≥5.0 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions</title>
          <description>The primary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥5.0 x 10^6 cells/kg was collected within the first 4 leukapheresis sessions. For the primary efficacy endpoint, each patient’s CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.</description>
          <population>There were total 9 MM patients and 3 NHL or HD patients . A MM patient was treated with Revlimid, Following 2 leukapheresis sessions, a cumulative total of 0.18 x 10^6 cells/kg were collected. PI and Medical Monitor didn't feel that further leukapheresis sessions would achieve more cells, so the patient didn't have additional sessions.</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50000" lower_limit="0.2109" upper_limit="0.7891"/>
                    <measurement group_id="O2" value="0.9167" lower_limit="0.6152" upper_limit="0.9979"/>
                    <measurement group_id="O3" value="0.9167" lower_limit="0.6152" upper_limit="0.9979"/>
                    <measurement group_id="O4" value="0.9167" lower_limit="0.6152" upper_limit="0.9979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Myeloma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6667" lower_limit="0.2993" upper_limit="0.9251"/>
                    <measurement group_id="O2" value="0.8889" lower_limit="0.5175" upper_limit="0.9972"/>
                    <measurement group_id="O3" value="0.8889" lower_limit="0.5175" upper_limit="0.9972"/>
                    <measurement group_id="O4" value="0.8889" lower_limit="0.5175" upper_limit="0.9972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hodgkin Lymphoma or Hodgkin Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O2" value="1.0000" lower_limit="0.2924" upper_limit="1.0000"/>
                    <measurement group_id="O3" value="1.0000" lower_limit="0.2924" upper_limit="1.0000"/>
                    <measurement group_id="O4" value="1.0000" lower_limit="0.2924" upper_limit="1.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients From Whom a Total Number of CD34+ Cells ≥2.5 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions</title>
        <description>The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥2.5 x 10^6 cells/kg was collected within the first 4 leukapheresis sessions. Each patient’s CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.</description>
        <time_frame>Day 5 to Day 8</time_frame>
        <population>There were total 9 MM patients and 3 NHL or HD patients . A MM patient was treated with Revlimid, Following 2 leukapheresis sessions, a cumulative total of 0.18 x 10^6 cells/kg were collected. PI and Medical Monitor didn't feel that further leukapheresis sessions would achieve more cells, so the patient didn't have additional sessions.</population>
        <group_list>
          <group group_id="O1">
            <title>Within 1 Leukapheresis Session</title>
            <description>Cumulative CD34+ cell counts ≥2.5 x 10^6 cells/kg within 1 leukapheresis session</description>
          </group>
          <group group_id="O2">
            <title>Within 2 Leukapheresis Sessions</title>
            <description>Cumulative CD34+ cell counts ≥2.5 x 10^6 cells/kg within 2 leukapheresis session</description>
          </group>
          <group group_id="O3">
            <title>Within 3 Leukapheresis Sessions</title>
            <description>Cumulative CD34+ cell counts ≥2.5 x 10^6 cells/kg within 3 leukapheresis session</description>
          </group>
          <group group_id="O4">
            <title>Within 4 Leukapheresis Sessions</title>
            <description>Cumulative CD34+ cell counts ≥5.0 x 10^6 cells/kg within 4 leukapheresis session</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients From Whom a Total Number of CD34+ Cells ≥2.5 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions</title>
          <description>The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥2.5 x 10^6 cells/kg was collected within the first 4 leukapheresis sessions. Each patient’s CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) the first 4 leukapheresis sessions.</description>
          <population>There were total 9 MM patients and 3 NHL or HD patients . A MM patient was treated with Revlimid, Following 2 leukapheresis sessions, a cumulative total of 0.18 x 10^6 cells/kg were collected. PI and Medical Monitor didn't feel that further leukapheresis sessions would achieve more cells, so the patient didn't have additional sessions.</population>
          <units>Proportion of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9167" lower_limit="0.6152" upper_limit="0.9979"/>
                    <measurement group_id="O2" value="0.9167" lower_limit="0.6152" upper_limit="0.9979"/>
                    <measurement group_id="O3" value="0.9167" lower_limit="0.6152" upper_limit="0.9979"/>
                    <measurement group_id="O4" value="0.9167" lower_limit="0.6152" upper_limit="0.9979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Myeloma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8889" lower_limit="0.5175" upper_limit="0.9972"/>
                    <measurement group_id="O2" value="0.8889" lower_limit="0.5175" upper_limit="0.9972"/>
                    <measurement group_id="O3" value="0.8889" lower_limit="0.5175" upper_limit="0.9972"/>
                    <measurement group_id="O4" value="0.8889" lower_limit="0.5175" upper_limit="0.9972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hodgkin Lymphoma or Hodgkin Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0000" lower_limit="0.2924" upper_limit="1.0000"/>
                    <measurement group_id="O2" value="1.0000" lower_limit="0.2924" upper_limit="1.0000"/>
                    <measurement group_id="O3" value="1.0000" lower_limit="0.2924" upper_limit="1.0000"/>
                    <measurement group_id="O4" value="1.0000" lower_limit="0.2924" upper_limit="1.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Mobilized the Targeted Total Number of CD34+ Cells (≥6.0 x 10^6 Cells/kg) Within 5 Leukapheresis Sessions</title>
        <description>The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥6.0 x 10^6 cells/kg was collected within 5 leukapheresis sessions. Each patient’s CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) 5 leukapheresis sessions.</description>
        <time_frame>Day 5 to Day 9</time_frame>
        <population>There were total 9 MM patients and 3 NHL or HD patients . A MM patient was treated with Revlimid, Following 2 leukapheresis sessions, a cumulative total of 0.18 x 10^6 cells/kg were collected. PI and Medical Monitor didn't feel that further leukapheresis sessions would achieve more cells, so the patient didn't have additional sessions.</population>
        <group_list>
          <group group_id="O1">
            <title>Within 1 Leukapheresis Session</title>
            <description>Cumulative CD34+ cell counts ≥6.0 x 10^6 cells/kg within 1 leukapheresis session</description>
          </group>
          <group group_id="O2">
            <title>Within 2 Leukapheresis Sessions</title>
            <description>Cumulative CD34+ cell counts ≥6.0 x 10^6 cells/kg within 2 leukapheresis session</description>
          </group>
          <group group_id="O3">
            <title>Within 3 Leukapheresis Sessions</title>
            <description>Cumulative CD34+ cell counts ≥6.0 x 10^6 cells/kg within 3 leukapheresis session</description>
          </group>
          <group group_id="O4">
            <title>Within 4 Leukapheresis Sessions</title>
            <description>Cumulative CD34+ cell counts ≥6.0 x 10^6 cells/kg within 4 leukapheresis session</description>
          </group>
          <group group_id="O5">
            <title>Within 5 Leukapheresis Sessions</title>
            <description>Cumulative CD34+ cell counts ≥6.0 x 10^6 cells/kg within 5 leukapheresis session</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Mobilized the Targeted Total Number of CD34+ Cells (≥6.0 x 10^6 Cells/kg) Within 5 Leukapheresis Sessions</title>
          <description>The secondary efficacy endpoint was the proportion of patients from whom a total number of CD34+ cells ≥6.0 x 10^6 cells/kg was collected within 5 leukapheresis sessions. Each patient’s CD34+ cell number was calculated as the sum of CD34+ cell numbers collected from (up to) 5 leukapheresis sessions.</description>
          <population>There were total 9 MM patients and 3 NHL or HD patients . A MM patient was treated with Revlimid, Following 2 leukapheresis sessions, a cumulative total of 0.18 x 10^6 cells/kg were collected. PI and Medical Monitor didn't feel that further leukapheresis sessions would achieve more cells, so the patient didn't have additional sessions.</population>
          <units>Proportion of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5000" lower_limit="0.2109" upper_limit="0.7891"/>
                    <measurement group_id="O2" value="0.6667" lower_limit="0.3489" upper_limit="0.9008"/>
                    <measurement group_id="O3" value="0.6667" lower_limit="0.3489" upper_limit="0.9008"/>
                    <measurement group_id="O4" value="0.6667" lower_limit="0.3489" upper_limit="0.9008"/>
                    <measurement group_id="O5" value="0.6667" lower_limit="0.3489" upper_limit="0.9008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple myeloma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6667" lower_limit="0.2993" upper_limit="0.9251"/>
                    <measurement group_id="O2" value="0.8889" lower_limit="0.5175" upper_limit="0.9972"/>
                    <measurement group_id="O3" value="0.8889" lower_limit="0.5175" upper_limit="0.9972"/>
                    <measurement group_id="O4" value="0.8889" lower_limit="0.5175" upper_limit="0.9972"/>
                    <measurement group_id="O5" value="0.8889" lower_limit="0.5175" upper_limit="0.9972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hodgkin Lymphoma or Hodgkin Disease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O2" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O3" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O4" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                    <measurement group_id="O5" value="0.0000" lower_limit="0.0000" upper_limit="0.0000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Pharmacodynamics (PD) Following Treatment With TG-0054 When Combined With G-CSF</title>
        <description>determine circulating CD34+ cell counts in peripheral blood</description>
        <time_frame>Day 5 (1st leukapheresis session) to Day 6 (2nd leukapheresis session)</time_frame>
        <population>There were 5 patients who achived target number of CD34+ cells (&gt;=5.0*10^6 cells/kg) within two leukapheresis sessions and therefore didn't undergo addtional sessions. Among 7 patients who undergone 6 sessions, there were 1 patient didn't collect blood sample at 4h, 6h post-infusion and post-leukapheresis, and 1 patient 6h post-infusion not done.</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-dose</title>
            <description>Circulating CD34+ Cell Count (cells/µL) in Peripheral Blood at Pre-dose timepoint</description>
          </group>
          <group group_id="O2">
            <title>4h Post-infusion</title>
            <description>Circulating CD34+ Cell Count (cells/µL) in Peripheral Blood at 4h post-infusion timepoint</description>
          </group>
          <group group_id="O3">
            <title>6h Post-infusion</title>
            <description>Circulating CD34+ Cell Count (cells/µL) in Peripheral Blood at 6h post-infusion timepoint</description>
          </group>
          <group group_id="O4">
            <title>Pre-leukapheresis</title>
            <description>Circulating CD34+ Cell Count (cells/µL) in Peripheral Blood at Pre-leukapheresis timepoint</description>
          </group>
          <group group_id="O5">
            <title>Post-leukapheresis</title>
            <description>Circulating CD34+ Cell Count (cells/µL) in Peripheral Blood at Post-leukapheresis timepoint</description>
          </group>
        </group_list>
        <measure>
          <title>the Pharmacodynamics (PD) Following Treatment With TG-0054 When Combined With G-CSF</title>
          <description>determine circulating CD34+ cell counts in peripheral blood</description>
          <population>There were 5 patients who achived target number of CD34+ cells (&gt;=5.0*10^6 cells/kg) within two leukapheresis sessions and therefore didn't undergo addtional sessions. Among 7 patients who undergone 6 sessions, there were 1 patient didn't collect blood sample at 4h, 6h post-infusion and post-leukapheresis, and 1 patient 6h post-infusion not done.</population>
          <units>cells/µL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 5 (1st leukapheresis session)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.50" lower_limit="1.00" upper_limit="123.00"/>
                    <measurement group_id="O2" value="43.50" lower_limit="0.00" upper_limit="141.00"/>
                    <measurement group_id="O3" value="42.00" lower_limit="1.00" upper_limit="122.00"/>
                    <measurement group_id="O4" value="60.50" lower_limit="1.00" upper_limit="206.00"/>
                    <measurement group_id="O5" value="35.50" lower_limit="3.00" upper_limit="119.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6 (2nd leukapheresis session)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.00" lower_limit="1.00" upper_limit="59.50"/>
                    <measurement group_id="O2" value="28.00" lower_limit="14.00" upper_limit="45.00"/>
                    <measurement group_id="O3" value="20.00" lower_limit="0.00" upper_limit="45.00"/>
                    <measurement group_id="O4" value="34.00" lower_limit="2.00" upper_limit="70.00"/>
                    <measurement group_id="O5" value="21.00" lower_limit="16.00" upper_limit="45.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>10 µg/kg/Day G-CSF Alone</title>
          <description>Days 1 through 4</description>
        </group>
        <group group_id="E2">
          <title>10 µg/kg/Day G-CSF + 3.14 mg/kg TG-0054</title>
          <description>Day 5 until end of study</description>
        </group>
        <group group_id="E3">
          <title>Overall</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Li-Wen Chang</name_or_title>
      <organization>TaiGen Biotechnology Co., Ltd.</organization>
      <phone>+886-2-8177-7072 ext 1227</phone>
      <email>lwchang@taigenbiotech.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

